EXPRESSION OF ER/PR/HER2, BASAL MARKERS AND ADHESION MOLECULES IN PRIMARY BREAST CANCER AND IN LYMPH NODES METASTASES: A COMPARATIVE IMMUNOHISTOCHEMICAL ANALYSIS

被引:16
|
作者
Adamczyk, Agnieszka [1 ]
Niemiec, Joanna [1 ]
Ambicka, Aleksandra [2 ]
Malecki, Krzysztof [3 ]
Wysocki, Wojciech H. [4 ]
Mitus, Jerzy [4 ]
Rys, Janusz [2 ]
机构
[1] Maria Sklodowska Curie Mem Inst Oncol, Dept Appl Radiobiol, Ctr Oncol, Cracow Branch, PL-31115 Krakow, Poland
[2] Maria Sklodowska Curie Mem Inst Oncol, Dept Tumor Pathol, Ctr Oncol, Cracow Branch, PL-31115 Krakow, Poland
[3] Univ Children Hosp Cracow, Dept Radiotherapy, Krakow, Poland
[4] Maria Sklodowska Curie Mem Inst Oncol, Dept Surg Oncol, Ctr Oncol, Cracow Branch, PL-31115 Krakow, Poland
关键词
primary breast tumour; lymph node metastasis; basal markers; adhesion molecules; IN-SITU HYBRIDIZATION; MATCHED PRIMARY; PRIMARY TUMORS; HER-2; OVEREXPRESSION; MAINTENANCE; PROGRESSION; SIGNATURE; CARCINOMA; THERAPY;
D O I
10.5114/PJP.2012.32769
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The immunophenotypic differences between primary and metastatic tumour cells could influence patient's treatment or/and the results of selected diagnostic procedures. That prompted us to investigate potential differences between primary tumours and corresponding synchronous lymph node metastases in the T >= 1/N + /M0 breast cancer patients. The investigated group consisted of 108 patients with invasive ductal breast cancer, who underwent radical surgery. The expression of ER, PR, HER2 as well as CK5/6, P-cadherin, EGFR and Ep-CAM was assessed immunohistochemically. Our data suggest that ER, PR, HER2, EGFR and CK5/6 are expressed conservatively, with some minor changes between primary tumour and simultaneous lymph node metastases. On the contrary, Ep-CAM and P-cadherin immunoreactivity in primary and metastatic cells varied significantly. This variation might exclude Ep-CAM and P-cadherin as potential diagnostic or therapeutic targets.
引用
收藏
页码:228 / 234
页数:7
相关论文
共 50 条
  • [21] Breast cancer ER, PR, and HER2 expression variance by germline cancer predisposition genes.
    Wei, Grace
    Rosa, Marilin
    Chang, Maxine
    Czerniecki, Brian J.
    Wang, Xia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] ER, PR, Her2, and Ki-67 Expression in Male and Female Breast Cancer
    Lockyer, M. G.
    Martinez-Blanco, E.
    Verstovsek, G.
    Bedrosian, I.
    Albarracin, C.
    Rosen, D.
    LABORATORY INVESTIGATION, 2013, 93 : 54A - 55A
  • [23] ER, PR, Her2, and Ki-67 Expression in Male and Female Breast Cancer
    Lockyer, M. G.
    Martinez-Blanco, E.
    Verstovsek, G.
    Bedrosian, I.
    Albarracin, C.
    Rosen, D.
    MODERN PATHOLOGY, 2013, 26 : 54A - 55A
  • [24] The presence of internal controls for breast markers, not including breast biomarkers ER, PR, and Her2
    Yogananda, P. N.
    Maddumage, H.
    Veidemanis, R.
    Di Palma, S.
    JOURNAL OF PATHOLOGY, 2024, 264 : S10 - S10
  • [25] Comparative Analysis of Four Immunohistochemical Assays for HER2 Expression in Breast Carcinoma - Correlation with HER2 Gene Amplification and Perspectives for HER2 Low Expression
    Nielsen, Soren
    Wang, Diana
    Calero, Valeria Montalvo
    LaMar, Jared
    Saxena, Ashish
    Decamillis, Rina
    Stensballe, Mia
    LABORATORY INVESTIGATION, 2023, 103 (03) : S192 - S192
  • [26] Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis
    Zi-xiang Yao
    Lin-jie Lu
    Rui-jue Wang
    Liang-bin Jin
    Sheng-chun Liu
    Hong-yuan Li
    Guo-sheng Ren
    Kai-nan Wu
    De-lin Wang
    Ling-quan Kong
    Medical Oncology, 2014, 31
  • [27] Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis
    Yao, Zi-xiang
    Lu, Lin-jie
    Wang, Rui-jue
    Jin, Liang-bin
    Liu, Sheng-chun
    Li, Hong-yuan
    Ren, Guo-sheng
    Wu, Kai-nan
    Wang, De-lin
    Kong, Ling-quan
    MEDICAL ONCOLOGY, 2014, 31 (01)
  • [28] Branched-chain Assay for ER, PR, and HER2 RNA Levels is a Useful Adjunct in the Evaluation of ER, PR, and HER2 in Breast Cancer
    Yim, Hyeon Woo
    Song, Byung Joo
    Jung, Sang Seol
    Kim, Hyun-Joo
    Choi, Yeong-Jin
    Lee, Kyo-Young
    Lee, Ahwon
    JOURNAL OF BREAST CANCER, 2010, 13 (03) : 267 - 274
  • [29] Discordant ER, PR, and HER2 status between primary and metastatic breast cancer as prognostic factor
    Shin, Hee-Chul
    Han, Wonshik
    Moon, Hyeong-Gon
    Im, Seock-Ah
    Moon, Woo Kyung
    Park, In-Ae
    Park, Sung Jun
    Noh, Dong Young
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [30] Correlation of FOXA1 protein expression and ER, PR and Her2 expression in breast cancer patients
    Mohsin, Mohammed A.
    Zayed, Karrar S.
    JOURNAL OF PHARMACEUTICAL NEGATIVE RESULTS, 2022, 13 (03) : 433 - 436